Latest Ipos News

Regener8 Resources appoints Dave Malesic as Managing Director and CEO, aiming to accelerate its Balkan exploration program and unlock value at the Srebrenica North Project.

Daly Resources advances exploration across 6,451 km² in the Northern Territory, revealing fluorite assays up to 95.1% CaF₂ and significant copper-zinc potential backed by strategic investors and government funding.

CurveBeam AI’s FY2026 results show a 28% revenue decline and a 12% increase in net loss, while advancing its China commercialisation and robotic surgery integration strategies. The company also announced a $6-7 million capital raise post-year-end.

Ceretas Limited posted a $1.63 million net loss for FY26 on $1.28 million revenue from government grants, advancing its clinical-stage Alzheimer’s ultrasound platform. The company completed an $8 million IPO in July to fund pivotal trials and device development.

Carma Limited posted a 59% revenue jump to $113.8 million in FY26, doubling gross profit to $10.5 million, while gearing up to double reconditioning capacity and target positive EBITDA in 2027.

Nexsen Limited (ASX:NXN) reported a 30% rise in net loss to $6.55 million for FY26, driven by ongoing investment in its Group B Streptococcus rapid diagnostic and Asia-Pacific growth initiatives following its October 2025 IPO.

SSH Group delivered a 23% revenue increase and 79% profit rise in FY26, fueled by the strategic acquisition of Elphinstone Mechanical Services and strengthened partnerships.

Moonlight Resources Ltd (ASX: ML8) completed its first year as a listed entity, rapidly expanding its gold and copper exploration at the Clermont Project in Queensland. The company reported a net loss of $1.98 million for FY2026, reflecting active exploration and corporate growth following its December 2025 IPO.

Boresight Ltd (ASX: BST) recorded a 46% increase in revenue to $6.38 million for FY26, driven by global sales expansion and strategic investments including an $8 million IPO. Despite this growth, the company posted a $6.66 million net loss, largely due to increased operational expenses and significant share-based payments.

WAM Alternative Assets nearly doubled its pre-tax profit in FY2026, driven by a 9.1% portfolio gain and a decisive shareholder vote backing its strategy. The company declared a 6.0 cents per share dividend, partially franked at 60%, reflecting portfolio maturation and diversification.

Saluda Medical delivered FY26 revenue of US$90.2 million, beating guidance with strong US and international growth, while reporting a flat net loss of US$149.6 million amid ongoing heavy investment. The company’s FDA approval of its CAP24 paddle lead opens a new US surgical market segment.

Sea Forest Limited (ASX:SEA) reported a spectacular 486% surge in SeaFeed revenue for FY26, underpinned by 131,000 cattle committed, surpassing breakeven targets, and a robust $27.8 million cash buffer. The company advances its commercial footprint domestically and internationally, with carbon credit revenue set to kick off in late 2027.